Therapy-related acute lymphoblastic leukemia with MLL rearrangement following treatment of Burkitt's leukemia.
The occurrence of therapy-related acute lymphoblastic leukemia (ALL) is rare and, to our knowledge, is not reported in patients treated for Burkitt's leukemia. We report on a child with ALL with translocation t(4;11)(q21;q23) involving the MLL gene, 13 months after chemotherapy for Burkitt's leukemia. This present observation indicates that caution should be exercised in using high cumulative doses of DNA topoisomerase II inhibitors in such patients.
Millot
Frederic
F
Service d'Oncologie Hématologique et de Thérapie Cellulaire, Universitary Hospital, Poitiers, France. f.millot@chu-poitiers.fr
Brizard
Francoise
F
Sorel
Nathalie
N
Preudhomme
Claude
C
Cividin
Marie
M
Guilhot
Francois
F
Brizard
Andre
A
D002051:Burkitt Lymphoma / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D002648:Child; D002894:Chromosomes, Human, Pair 4; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D008297:Male; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics* / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000235:genetics* / Q000628:therapy*; D013997:Time Factors; D059005:Topoisomerase II Inhibitors; D014178:Translocation, Genetic; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; C497422:KMT2A protein, human; D059005:Topoisomerase II Inhibitors; D051788:Myeloid-Lymphoid Leukemia Protein; D011495:Histone-Lysine N-Methyltransferase